TCAF2

TCAF2 is a TRPM8 channel-associated factor that modulates ion channel trafficking and gating to shape cellular Ca²⁺ signaling, migration, and metastatic behavior. TCAF2 binds directly to TRPM8 and promotes its surface trafficking while suppressing channel gating activity, thereby reducing intracellular Ca²⁺ signals and promoting cell migration and invasion — effects opposing those of the related factor TCAF1 (PMID:25559186). In tumor pericytes, TCAF2-mediated inhibition of TRPM8 drives Wnt5a secretion, which activates STAT3 signaling in neighboring tumor cells to promote epithelial-mesenchymal transition and colorectal cancer liver metastasis, as demonstrated by pericyte-conditional Tcaf2-knockout mice and pharmacological TRPM8 agonist rescue (PMID:37635201). TCAF2 also activates the JAK2/STAT3 pathway in glioma and gastric cancer cells, and its expression is positively regulated by PDE12, positioning it as a convergent effector in STAT3-dependent oncogenic programs (PMID:38019450, PMID:40628363).

1. 2015 High

   Establishing that TCAF2 is a direct TRPM8-binding protein that promotes channel surface trafficking yet opposes TCAF1 in gating regulation and cell migration resolved how functionally antagonistic channel modulators share the same target to produce divergent migratory outcomes.

   Evidence Co-immunoprecipitation, functional channel assays, and cell migration assays in prostate cancer cells

   PMID:25559186

   Open questions at the time

   • Binding interface between TCAF2 and TRPM8 is structurally undefined
   • Mechanism by which TCAF2 suppresses TRPM8 gating while promoting trafficking is unknown
   • Whether TCAF2 affects TRPM8 independently of TCAF1 competition was not resolved
2. 2023 High

   Demonstrating that TCAF2 in pericytes inhibits TRPM8 to drive Wnt5a secretion and paracrine STAT3-dependent EMT in colorectal cancer cells established a non-cell-autonomous mechanism linking TCAF2-TRPM8 axis to metastasis in vivo.

   Evidence Pericyte-conditional Tcaf2-knockout mice, TRPM8 activity assays, Wnt5a measurement, STAT3 pathway analysis, menthol rescue in colorectal cancer liver metastasis model

   PMID:37635201

   Open questions at the time

   • How TCAF2 inhibition of TRPM8 mechanistically triggers Wnt5a secretion is not defined
   • Whether the pericyte-specific role generalizes to other stromal cell types is untested
   • Direct structural or biochemical evidence for TCAF2-induced conformational changes in TRPM8 is absent
3. 2023 Medium

   Showing TCAF2 promotes glioma migration and invasion via STAT3 activation and EMT extended the STAT3-effector role of TCAF2 to a TRPM8-independent or uncharacterized context in a different cancer type.

   Evidence Transwell/scratch assays with knockdown/overexpression, western blotting for EMT markers and STAT3 phosphorylation in glioma cells

   PMID:38019450

   Open questions at the time

   • Whether TRPM8 mediates TCAF2's effects in glioma was not tested
   • No direct binding partner or upstream signal for TCAF2 in glioma was identified
   • Single-lab study without independent replication
4. 2025 Medium

   Identifying PDE12 as a positive transcriptional regulator of TCAF2 and showing epistasis over JAK2/STAT3 in gastric cancer placed TCAF2 within a defined upstream-downstream signaling hierarchy for the first time.

   Evidence TCAF2 knockdown rescue of PDE12 overexpression phenotype, western blotting for JAK2/STAT3 in gastric cancer cells

   PMID:40628363

   Open questions at the time

   • Mechanism by which PDE12 regulates TCAF2 expression is uncharacterized
   • Whether JAK2/STAT3 activation by TCAF2 requires TRPM8 interaction is unknown
   • Single-lab study without independent replication

• The molecular mechanism by which TCAF2 modulates TRPM8 gating, the structural basis of the TCAF2-TRPM8 interaction, and the pathway connecting TCAF2 to JAK2/STAT3 activation independently of TRPM8 remain undefined.
• No structural model or cryo-EM data for TCAF2 or the TCAF2-TRPM8 complex
• Whether TCAF2 has direct enzymatic or adaptor activity beyond channel modulation is unknown
• In vivo validation of the PDE12-TCAF2-JAK2/STAT3 axis is lacking